Related Experiment Video

Updated: May 6, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

9.8K

Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants

R Gold, M L Lepow, I Goldschneider

    The Journal of Clinical Investigation
    |December 1, 1975
    PubMed

    Insights

    Infant meningococcal polysaccharide vaccines (A and C) showed good safety. Antibody responses varied by age, with older infants demonstrating stronger immunity to vaccine A and C.

    Area of Science:

    • Immunology
    • Vaccinology
    • Pediatrics

    Background:

    • Meningococcal disease remains a significant public health concern, particularly in infants.
    • Polysaccharide vaccines against Neisseria meningitidis serogroups A and C are available, but their efficacy in infants requires careful evaluation.
    • Understanding infant immune responses to these vaccines is crucial for optimizing vaccination strategies.

    Purpose of the Study:

    • To evaluate the safety and immunogenicity of Group A and Group C meningococcal polysaccharide vaccines in infants.
    • To determine the factors influencing antibody response, including infant age, vaccine dose, and prior exposure.
    • To establish optimal dosing and identify potential limitations for infant vaccination.

    Main Methods:

    • A total of 908 doses of Group A and C meningococcal polysaccharide vaccines were administered to 396 infants aged 3 to 12 months.
    • Local and systemic reactions were monitored post-vaccination.
    • Antibody responses (geometric mean concentrations) were measured at various time points and correlated with age, vaccine dose, and prior antigen exposure.

    Main Results:

    • No significant local or systemic reactions were observed across all vaccine doses and age groups.
    • Infant antibody response to Group A vaccine increased significantly with age, with 7- and 12-month-olds showing >90% response rates.
    • Group C vaccine elicited a strong response in 3-month-olds, with 100 mcg appearing optimal, but booster doses did not enhance antibody levels.
    • Maternal antibodies appeared to suppress responses in younger infants for Group A vaccine.

    Conclusions:

    • Meningococcal polysaccharide vaccines (A and C) are safe for infants aged 3-12 months.
    • Age is a critical factor in achieving adequate antibody responses, particularly for Group A vaccine.
    • The 100 mcg dose of Group C vaccine is recommended for primary immunization, while booster responses are limited.
    • Further research into optimizing infant vaccination schedules and overcoming maternal antibody interference is warranted.

    More Related Videos

    Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery10:03

    Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

    Published on: November 5, 2019

    7.0K
    Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

    Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

    Published on: May 19, 2020

    3.0K

    Related Concept Videos

    Viral Meningitis01:18

    Viral Meningitis

    Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
    219
    Bacterial Meningitis I: Introduction01:22

    Bacterial Meningitis I: Introduction

    Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
    32
    Bacterial Meningitis II: Pathophysiology01:26

    Bacterial Meningitis II: Pathophysiology

    Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
    49